Insmed Inc. is Today's Focus Stock on MicroStockProfit.com
14 Juin 2011 - 12:50PM
MicroStockProfit.com announces an investment report featuring
Insmed Inc. (Nasdaq:INSM). The report includes financial,
comparative and investment analyses, and industry information you
need to know to make an educated investment decision.
The full report is available at:
www.microstockprofit.com/lp/INSM
Insmed Inc. (INSM) is a biopharmaceutical company focused on the
development of innovative inhaled pharmaceuticals for the
site-specific treatment of serious lung diseases. The Company's
primary focus is on the development of inhaled antibiotic therapy
delivered via proprietary advanced pulmonary liposome technology in
areas of high unmet need in lung diseases. INSM's lead product
candidate ARIKACE is an inhaled antibiotic supported by positive
phase II results for treating serious lung infections due to
susceptible bacteria.
This newsletter has been helping traders make great investment
decisions on INSM; click here for a 25% discount offer.
In the report, the analyst notes:
"INSM saw its stock rise more than 12% in Monday's trading after
the Company last Friday announced positive data through six
treatment cycles (72 weeks total duration) of its phase II clinical
trial program for ARIKACE in cystic fibrosis (CF) patients with
Pseudomonas lung infections. Predrag Minic, M.D., professor of
Pediatrics and head of Pediatrics Pulmonology Department, Mother
and Child Health Institute, Belgrade, Serbia, and co-lead
investigator of the study, presented the data at the 34th European
Cystic Fibrosis Conference in Hamburg, Germany."
"According to the release, the data demonstrated that ARIKACE,
delivered once-daily for 28 consecutive days, followed by 56 days
off-treatment, for a total of six cycles, resulted in statistically
significant improvement in lung function that was sustained over a
72-week period."
To read the entire report visit:
www.microstockprofit.com/lp/INSM
See what investors are saying about INSM at
http://www.stockhideout.com
Get breaking news on INSM at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment
commentary provider. MicroStockProfit.com strives to provide a
balanced view of many promising small-cap companies that would
otherwise fall under the radar of the typical Wall Street investor.
We provide investors with an excellent first step in their research
and due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
information on MicroStockProfit please visit:
http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. MicroStockProfit.com
is a Web site wholly owned by BlueWave Advisors, LLC. Neither
MicroStockProfit.com nor its affiliates have a beneficial interest
in the mentioned company; nor have they received compensation of
any kind for any of the companies listed in this communication.
Please read our report and visit our Web site,
MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Brian Johnson
info@microstockprofit.com
1-888-307-2850
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024